Merck stock trades steady as oncology and vaccines drive growth

Merck & Co., Inc. (ISIN US58933Y1055) is a major US pharmaceutical group whose Merck stock is widely followed on the New York Stock Exchange. The company reported solid top line expansion in its latest full-year figures, with total revenue reaching around $60 billion in 2023 compared with roughly $59 billion in 2022, helped by strong demand for its oncology and vaccines portfolio. For investors, the balance between patent life of key brands and the next wave of launches remains central to the medium-term view on Merck stock.

Oncology revenue approaches $30 billion

Merck & Co., Inc. has built its current growth profile largely around its immuno-oncology medicine Keytruda, which has become one of the largest-selling prescription drugs globally. In the companys recent annual reporting, Keytruda generated on the order of $25 billion to $30 billion in 2023, up from the low to mid $20 billion range in 2022, marking double-digit percentage growth year on year. That performance underscores how much of Mercks revenue base now comes from oncology, a segment that has seen steady uptake across multiple cancer indications.

The growth of Keytruda has also reshaped Mercks margin structure. Because branded oncology therapies typically carry higher gross margins than more mature primary-care portfolios, the expansion of oncology revenue has supported operating profitability even as legacy franchises face pricing pressure. In broad terms, Merck has been able to sustain operating margins in the mid to high twenties percent in recent reporting periods, reflecting a mix of high-value oncology sales alongside vaccines and hospital products. For investors, the magnitude of Keytrudas contribution and its patent timeline are essential factors when analyzing Merck stock in a longer horizon.

Revenue growth balanced by vaccines and animal health

Beyond oncology, Merck & Co., Inc. reports meaningful contributions from its vaccines and animal health businesses, which together provide diversification against therapeutic-specific risks. In its latest annual breakdown, vaccines revenue has been running in a high single-digit billion dollar range, broadly similar to the prior year, with modest growth driven by products such as Gardasil for human papillomavirus prevention. Animal health, which includes parasiticides and vaccines for livestock and companion animals, has contributed several billion dollars of annual sales, providing a more stable, less patent-sensitive income stream.

The overall mix means that Merck has been able to deliver low single-digit to mid single-digit percentage total revenue growth from 2022 to 2023, while keeping its portfolio weighted toward patented medicines and biologicals. That is important for the cash flow profile: Mercks latest reporting showed operating cash flow in the tens of billions of dollars in 2023, broadly in line with or moderately above 2022, giving management flexibility to invest in research and development, business development, and shareholder returns. Over the years, Merck has raised its dividend periodically, and the cash generated by oncology and vaccines has helped underpin that policy.

Keytruda and Gardasil underpin the portfolio

Keytruda is Merck & Co., Inc.s flagship immunotherapy for multiple cancers, including melanoma, lung cancer, and certain head and neck cancers. Its continued revenue growth reflects both expanded labeled indications and broader adoption in clinical practice, where it is often used in combination with chemotherapy or targeted agents. The annual sales figures in the mid to high tens of billions of dollars underscore the drugs central role in Mercks earnings and cash flow generation, even as competitors develop their own checkpoint inhibitors and immuno-oncology combinations.

Vaccines, particularly Gardasil, form another pillar of Mercks business. Gardasil, which prevents infection with high-risk HPV types associated with cervical and other cancers, has brought in billions of dollars in annual sales based on widespread immunization programs. Together with pediatric and adult vaccines, this franchise provides recurring, program-driven demand that can be less sensitive to economic cycles than some discretionary healthcare spending. The combination of oncology, vaccines, and animal health gives Merck a multi-pronged portfolio where different segments can offset each other if one faces temporary headwinds.

Merck stock and valuation context

Merck stock represents a claim on this diversified cash flow base, and valuation often benchmarks the company against other large-cap pharmaceutical peers. Market participants frequently compare Mercks revenue and earnings growth with those of companies such as Pfizer, Bristol Myers Squibb, or Johnson & Johnson to assess relative performance. With total revenue in the ballpark of $60 billion and a major oncology asset generating around half of that, Merck tends to be classified as a growth-focused pharma within the broader defensive healthcare sector.

From a balance sheet perspective, the steady cash flow from oncology and vaccines helps support research spending and external collaboration. Mercks annual research and development expense has run into the double-digit billions of dollars, which is necessary to sustain innovation across oncology, vaccines, cardiometabolic, and other therapeutic areas. Investors who follow Merck stock often look at the ratio of R&D spending to revenue as a signal of the companys long-term commitment to innovation, alongside more immediate metrics such as earnings per share and free cash flow.

Keytruda cancer therapy

Among its products, Keytruda is the most prominent representative of Merck & Co., Inc.s portfolio for equity investors. The drug has changed treatment paradigms in several cancers by targeting the PD-1 pathway to unleash the immune system against tumors. Its revenue trajectory, moving from the low tens of billions of dollars earlier in its life cycle to the mid to high tens of billions in recent years, shows both the commercial potential of breakthrough cancer medicines and the importance of continued label expansion and combination strategy.

Merck stock price and market capitalization

Merck stock, traded on the New York Stock Exchange under the symbol MRK, is backed by a large market capitalization that reflects its size and diversified earnings base. The shares are typically included in major US indices, and the companys valuation is closely watched by institutional and retail investors alike. Over recent years, the stock has seen periods of appreciation as oncology and vaccines delivered growth as well as phases of consolidation when patent timelines and competitive dynamics weighed on sentiment. Ultimately, Merks revenue scale, cash generation, and investment in its pipeline form the foundation of how the market prices Merck stock.